First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics Net sales rise 11% (+2% in local currencies) to USD 20. 6 billion Operating income advances 12% to USD 4. 9 billion on business expansion, productivity gains and currency benefits Net income up 13% to USD 4. 6 billion; basic EPS rises 17% to USD 2. 01 Dynamic growth from new products - including Tekturna/Rasilez, Exforge, Lucentis, Exelon Patch and Aclasta/Reclast - provides USD 1. 3 billion in first-half net sales Key R&D projects on track for 2008 submissions, particularly Afinitor (RAD001) for advanced kidney cancer and Menveo meningococcal meningitis vaccine 25% stake in Alcon, the world leader in eye care, purchased in July; strategic acquisitions strengthen portfolio and complement internal growth drivers Novartis on track for record sales and earnings in 2008 from continuing operations Key figures - Continuing operations First half H1 2008 H1 2007 % change USD m % of net sales USD m % of net sales USD lc Net sales 20 635 18 528 11 2 Operating income 4 949 24. ben 1000 games casino blackjack casino chicago europe online travel travel gambling effects on america gambling news in florida american attitudes about gambling